Clinical trial
CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation
NCT00227344 · Biosense Webster EMEA, Industry · Terminated
Key facts
| NCT number | NCT00227344 |
|---|---|
| Title | CACAF2 Study: Catheter Ablation for Cure of Atrial Fibrillation |
| Official title | Catheter Ablation for Cure of Atrial Fibrillation |
| Acronym | CACAF-2 |
| Lead sponsor | Biosense Webster EMEA, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Device, Drug |
| Interventions | RF ablation, Antiarrhythmic drugs |
| Enrollment | 129 |
| Start date | Dec 1, 2004 |
| Primary completion | Oct 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Sep 28, 2005 |
| Last update posted | Feb 4, 2025 |
At a glance
- Yes Results posted
- 10–99 Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: